With fenebrutinib, the company aims to launch a new oral treatment for multiple sclerosis that offers both greater ...

Liver-related side effects have led some analysts to question fenebrutinib’s prospects, even though the drug has now cleared Phase 3 studies in multiple forms of the disease.

When ocrelizumab became the first FDA-approved treatment for early forms of multiple sclerosis (MS) in 2017, it offered patients immense hope. The long-awaited drug is a monoclonal antibody that ...

Biogen and Alkermes won approval Oct. 30 for their new multiple sclerosis drug, Vumerity, according to The Boston Globe. Vumerity is an oral drug designed to treat relapsing forms of MS, a chronic ...

FRANKFURT (Reuters) -Swiss drugmaker Roche said on Monday that a late-stage trial testing ‌its multiple sclerosis drug candidate fenebrutinib against the relapsing form ‌of the disease achieved its ...

Sanofi announced that the FDA has extended the regulatory review of its filing seeking approval to treat non-relapsing secondary progressive MS (nrSPMS) and slow disability accumulation independent of ...

On Monday, the U.S. Food and Drug Administration (FDA) extended the review date for Sanofi SA’s (NASDAQ:SNY) new drug application (NDA) of tolebrutinib for non-relapsing, secondary progressive ...

A generic version of multiple sclerosis drug Copaxone was introduced in 2015, but it has done little to lower drug costs for MS patients, NPR reported. Yearly costs for MS drugs can run as high as $50 ...

Shares of Sanofi slumped on Monday as the French drugmaker said a U.S. regulatory review of its multiple-sclerosis drug won’t be completed by the end of the year and a trial for a different form of MS ...

Living with multiple sclerosis (MS) often means managing a mix of symptoms that affect daily life, including fatigue, mobility challenges, pain, and changes in strength and endurance. Body weight can ...

By Ludwig Burger and Patricia Weiss FRANKFURT, March 5 (Reuters) - Germany's Merck KGaA projected 2026 adjusted operating profit to slip by as much as 9.8%, hurt by negative currency effects and the ...